Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
About Gilgamesh Pharmaceuticals
Gilgamesh is a pioneering, clinical stage mental health science-focused biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCEs) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.
Company details
Funding
Total raised
$88.2M
Last stage
Series A
Investors
Founders
Dalibor Sames
Professor of Chemistry at Columbia University with expertise in synthetic chemistry, medicinal chemistry, molecular design, synaptic imaging, neuropharmacology, and experimental therapeutics. Led new conceptual advances in chemical synthesis (C-H bond functionalization), developed fluorescent false neurotransmitters (FFNs), elucidated the mechanism of action of antidepressant tianeptine, expertise in iboga alkaloid and mitragynines chemistry and pharmacology.
Jonathan Sporn
MD; psychiatrist and neuroscientist; Assistant Professor of Psychiatry and Experimental Therapeutics at Columbia University; previously founded Perception Neuroscience (first exit in psychedelic space to ATAI Life Sciences).
LinkedIn
Andrew Kruegel
Medicinal chemist, pharmacologist, and entrepreneur with 15+ years of experience designing psychoactive drugs; previously Founder & CSO of Kures Therapeutics (acquired by ATAI).
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.